Ab-TCI

Ab-TCI: sourced facts only. name: "This Ab-TCI enables B-cell lymphoma cell recognition, internalization, and release of As-Ibt by intracellular GSH, efficiently inhibiting BTK, and effectively suppressing the growth of xenograft tumors." [PMID:42157842]; target: "This Ab-TCI enables B-cell lymphoma cell recognition, internalization, and release of As-Ibt by intracellular GSH, efficiently inhibiting BTK, and effectively suppressing the growth of xenograft tumors." [PMID:42157842]; developer: "Department of Chemistry and the MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China." [PMID:42157842]; modality: "we present a new cell/protein "Double Insurance" targeting strategy through constructing a novel antibody-TCI conjugate (Ab-TCI), which comprises a monoclonal antibody (Loncastuximab), a TCI (As-Ibt) for Bruton's tyrosine kinase (BTK), and between them an arsenic-thiol bond as a new cleavable linker." [PMID:42157842]; stage: "This Ab-TCI enables B-cell lymphoma cell recognition, internalization, and release of As-Ibt by intracellular GSH, efficiently inhibiting BTK, and effectively suppressing the growth of xenograft tumors." [PMID:42157842]